BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9723824)

  • 1. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
    Ridge SA; Sludden J; Brown O; Robertson L; Wei X; Sapone A; Fernandez-Salguero PM; Gonzalez FJ; Vreken P; van Kuilenburg AB; van Gennip AH; McLeod HL
    Br J Clin Pharmacol; 1998 Aug; 46(2):151-6. PubMed ID: 9723824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
    Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
    Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
    Collie-Duguid ES; Etienne MC; Milano G; McLeod HL
    Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.
    van Kuilenburg AB; Dobritzsch D; Meinsma R; Haasjes J; Waterham HR; Nowaczyk MJ; Maropoulos GD; Hein G; Kalhoff H; Kirk JM; Baaske H; Aukett A; Duley JA; Ward KP; Lindqvist Y; van Gennip AH
    Biochem J; 2002 May; 364(Pt 1):157-63. PubMed ID: 11988088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB; De Abreu RA; van Gennip AH
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.
    Morsman JM; Sludden J; Ameyaw MM; Githang'A J; Indalo A; Ofori-Adjei D; McLeod HL
    Br J Clin Pharmacol; 2000 Sep; 50(3):269-72. PubMed ID: 10971312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
    Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
    Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
    Wei X; McLeod HL; McMurrough J; Gonzalez FJ; Fernandez-Salguero P
    J Clin Invest; 1996 Aug; 98(3):610-5. PubMed ID: 8698850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
    van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
    Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.
    Van Kuilenburg AB; Van Lenthe H; Tromp A; Veltman PC; Van Gennip AH
    Clin Chem; 2000 Jan; 46(1):9-17. PubMed ID: 10620566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.
    Yamaguchi K; Arai Y; Kanda Y; Akagi K
    Jpn J Cancer Res; 2001 Mar; 92(3):337-42. PubMed ID: 11267945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
    Van Kuilenburg AB; Vreken P; Abeling NG; Bakker HD; Meinsma R; Van Lenthe H; De Abreu RA; Smeitink JA; Kayserili H; Apak MY; Christensen E; Holopainen I; Pulkki K; Riva D; Botteon G; Holme E; Tulinius M; Kleijer WJ; Beemer FA; Duran M; Niezen-Koning KE; Smit GP; Jakobs C; Smit LM; Van Gennip AH
    Hum Genet; 1999 Jan; 104(1):1-9. PubMed ID: 10071185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the human dihydropyrimidine dehydrogenase gene.
    Wei X; Elizondo G; Sapone A; McLeod HL; Raunio H; Fernandez-Salguero P; Gonzalez FJ
    Genomics; 1998 Aug; 51(3):391-400. PubMed ID: 9721209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.
    Vreken P; Van Kuilenburg AB; Meinsma R; van Gennip AH
    Hum Genet; 1997 Dec; 101(3):333-8. PubMed ID: 9439663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.